PBAC MEETING DECEMBER 2023 |
|
|
MEDICINE |
INDICATION |
STATUS |
MELATONIN Slenyto |
Insomnia |
No listing proposal received |
PATISIRAN Onpattroe |
Hereditary transthyretinmediated amyloidosis |
NO listing proposal received |
UPADACITINIB Rinvoq |
Rheumatoid arthritis |
Government processes commenced |
PBAC MEETING NOVEMBER 2023 |
|
|
MEDICINE |
INDICATION |
STATUS |
ABEMACICUB Verzenio |
Early breast cancer |
Government processes commenced |
ADALIMUMAB Hadlima |
Crohn disease; ulcerative colitis; severe active juvenile idiopathic arthritis; fistulising Crohn disease; rheumatoid arthritis; psoriatic arthritis; ankylosing spondylitis; chronic plaque psoriasis; hidradenitis suppurativa |
No listing proposal received |
APREMILAST Otezla |
Chronic plaque psoriasis |
Listing proposal under consideration |
BUDESONIDE + FORMOTEROL Bufomix Easyhaler |
Asthma; Chronic obstructive pulmonary disease |
Government processes commenced |
CEMIPUMAB Libtayo |
Non-small cell lung cancer |
Government processes commenced |
CHLORMETHINE HYDROCHLORIDE Ledaga |
Mycosis fungoides-type cutaneous T-cell lymphoma |
Listing proposal under consideration |
DAUNORUBICIN WITH CYTARABINE Vyxeos |
Acute myeloid leukaemia |
Listing proposal under consideration |
DIFELIKEFALIN Korsuva |
Chronic kidney disease associated pruritus |
Listing proposal under consideration |
DOSTARUMAB JemperlP |
Endometrial cancer |
Listing proposal under consideration |
ELTROMBOPAG Revolade |
Aplastic anaemia |
No listing proposal received |
EMPAGLIFLOZIN Jardiance |
Chronic kidney disease |
Listing proposal under consideration |
FLUTICASONE PROPIONATE SALMETEROL Salflumix Easyhalere |
Asthma; chronic obstructive pulmonary disease |
Government processes commenced |
IVACAFTOR Kalydecoe |
Cystic fibrosis (from 4 months) |
No listing proposal consistent with PBAC advice received |
LENACAPAVIR Sunlenca |
Human immunodeficiency virus (HIV) |
No listing proposal received |
LENAUDOMIDE Lenalide |
Multiple myeloma; myelodysplastic syndromes; mantle cell lymphoma |
Listing proposal under consideration |
MAVACAMTEN Camzyoss |
Hypertrophic cardiomyopathy |
Government processes commenced |
MEDROXYPROGESTERONE ACETATE Depo-provera |
Contraception; endometriosis |
Government processes commenced |
MIDAZOLAM Zyamis |
Generalised convulsive status epilepticus |
Listing proposal under consideration |
OLAPARIB Lynparzae |
Human epidermal growth factor receptor 2 (HER2)-negative early breast cancer |
Listing proposal under consideration |
OSIMERTINIB Tagrissoe |
Non-small cell lung cancer |
Listing proposal under consideration |
PEMBROUZUMAB Keytruda |
Squamous cell carcinoma |
No listing proposal received |
RISANKIZUMAB Skyrizi |
Chronic plaque psoriasis |
Listing proposal under consideration |
SECUKINUMAB Cosentyx |
Hidradenitis suppurativa |
No listing proposal received |
TERIPARATIDE Teriparatide Lupin |
Osteoporosis |
Listing proposal under consideration |
TERIPARATIDE Terrosae |
Osteoporosis |
Government processes commenced |
PBAC MEETING SEPTEMBER 2023 |
|
|
MEDICINE |
INDICATION |
STATUS |
CABOTEGRAVIR Apretude |
Pre-exposure prophylaxis (PrEP) for human immunodeficiency virus (HIV) infection |
No listing proposal consistent with PBAC advice received |
CHORIOGONADOTROPIN ALFA Ovidre |
Infertility indications other than that of Assisted Reproductive Technology (ART) |
Government processes commenced |
PBAC MEETING JULY 2023 |
|
|
MEDICINE |
INDICATION |
STATUS |
ABIRATERONE AND METHYLPREDNISOLONE Yonsa Mpred |
Metastatic hormone sensitive prostate cancer |
Government processes commenced |
DAPAGLIFLOZIN Forxiga |
Chronic heart failure |
Government processes commenced |
NIRAPARIB Zejula |
Epithelial ovarian, fallopian tube, or primary peritoneal cancer |
Government processes commenced |
NIVOLUMAB Opdivo |
Non-small cell lung cancer (neoadjuvant) |
NO listing proposal received The sponsor has made a further submission to the PBAC at its March 2024 meeting |
NUSINERSEN Spinraza |
Pre-symptomatic spinal muscular atrophy |
Government processes commenced |
SOMAPACITAN Sogroya |
Paediatric growth hormone deficiency |
No listing proposal consistent with PBAC advice received |
TAFAMIDIS Vyndamax |
Transthyretin amyloid cardiomyopathy |
Government processes commenced |
PBAC MEETING MAY 2023 |
|
|
MEDICINE |
INDICATION |
STATUS |
INCUSIRAN Leqvio |
Hypercholesterolaemia |
Government processes commenced |
PBAC MEETING MARCH 2023 |
|
|
MEDICINE |
INDICATION |
STATUS |
AUROCUMAB Praluent |
Hypercholesterolaemia (new forms) |
No listing proposal received |
AMINO ACID FORMULA WITH VITAMINS AND MINERALS WITHOUT VAUNE, LEUCINE AND ISOLEUCINE AND SUPPLEMENTED WITH ARACHIDONIC ACID AND DOCOSAHEXAENOIC ACID MISU D explore5 |
Maple syrup urine disease |
Government processes commenced |
AMINO ACID FORMULA WITH VITAMINS AND MINERALS, WITHOUT METHIONINE AND SUPPLEMENTED WITH ARACHIDONIC ACID AND DOCOSAHEXAENOIC ACID HCU explore5 |
Pyridoxine non-responsive homocystinuria |
Government processes commenced |
AMINO ACID FORMULA WITH VITAMINS AND MINERALS, WITHOUT PHENYLALANINE AND TYROSINE AND SUPPLEMENTED WITH ARACHIDONIC ACID AND DOCOSAHEXAENOIC ACID TYR explore5 |
Tyrosinaemia |
Government processes commenced |
ROMOSOZUMAB Evenity |
Osteoporosis |
No listing proposal consistent with PBAC advice received The sponsor has made a further submission to the PBAC for consideration at its March 2024 meeting |
PBAC MEETING DECEMBER 2022 |
|
|
MEDICINE |
INDICATION |
STATUS |
MIGALASTAT Galafold |
Fabry disease |
No listing proposal received The sponsor has made a further submission to the PBAC for consideration at its March 2024 meeting |
PBAC MEETING NOVEMBER 2022 |
|
|
MEDICINE |
INDICATION |
STATUS |
DUPILUMAB Dupixent |
Chronic severe atopic dermatitis Uncontrolled severe asthma (new form) |
No listing proposal received |
INFUXIMAB Remsimae SC |
Rheumatoid arthritis |
No listing proposal received |
RISANKIZUMAB Skyrizi |
Crohnis disease |
No listing proposal received |
PBAC MEETING JULY 2022 |
|
|
MEDICINE |
INDICATION |
STATUS |
HUMAN MENOPAUSAL GONADOTROPHIN Menopur 600 Menopur 1200 |
Assisted Reproductive Technology |
No listing proposal received |
USTEKINUMAB Stelara |
Severe Crohn disease, Severe chronic plaque psoriasis (new form) |
No listing proposal received |